[{"Final_set": {"Context": "A new mother brings her 1-month-old infant to the emergency department after noticing that he has been excessively crying, appears irritable, and has a distended abdomen. The mother reports that the baby is feeding well, but after several feeds, he often has episodes of intense crying followed by forceful vomiting. An abdominal ultrasound reveals a 'target sign' and narrowing at the pylorus. The infant is well-hydrated, with stable vital signs. Given the findings, it is suspected that the infant has a congenital gastrointestinal condition. Pyloric stenosis is characterized by narrowing of the pylorus due to muscle hypertrophy, leading to gastric outlet obstruction.", "Question": "What is the most likely diagnosis for this infant's condition based on the clinical evidence presented?", "Choices": ["A: Gastroesophageal reflux disease (GERD)", "B: Pyloric stenosis", "C: Meckel's diverticulum", "D: Intestinal obstruction due to an inguinal hernia"], "Answer": "B: Pyloric stenosis. This is the correct answer because the symptoms of excessive crying, forceful vomiting after feeds, and the ultrasound findings of a 'target sign' along with abdominal distension are characteristic of pyloric stenosis, which is a condition arising from hypertrophy of the pyloric muscle leading to gastric outlet obstruction. The age of the infant and the nature of the vomiting further support this diagnosis, distinguishing it from the other options."}, "context": "# Table of Contents\nList of Tables, Figures , and Boxes"}, {"Final_set": {"Context": "Preexposure Prophylaxis for HIV Prevention in the United States - 2013: A Clinical Practice Guideline provides comprehensive information for the use of daily oral antiretroviral preexposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection in adults. The key messages of the guideline are as follows: Daily oral PrEP with the fixed-dose combination of tenofovir disoproxil fumarate (TDF) 300 mg and emtricitabine (FTC) 200 mg has been shown to be safe and effective in reducing the risk of sexual HIV acquisition in adults; therefore, o PrEP is recommended as one prevention option for sexually-active adult MSM (men who have sex with men) at substantial risk of HIV acquisition (IA); PrEP is recommended as one prevention option for adult heterosexually active men and women who are at substantial risk of HIV acquisition (IA); PrEP is recommended as one prevention option for adult injection drug users (IDU) at substantial risk of HIV acquisition (IA); PrEP should be discussed with heterosexually-active women and men whose partners are known to have HIV infection (i.e., HIV-discordant couples) as one of several options to protect the uninfected partner during conception and pregnancy so that an informed decision can be made in awareness of what is known and unknown about benefits and risks of PrEP for mother and fetus (IIB); Currently the data on the efficacy and safety of PrEP for adolescents are insufficient.", "Question": "A 25-year-old man who is sexually active with multiple partners comes to an outpatient clinic for advice on preventing HIV infection. He expresses concern about his high risk of contracting HIV due to his lifestyle. Which of the following strategies would be most appropriate for him to reduce the risk of HIV acquisition?", "Choices": {"A": "Use of serological testing every three months without any other preventive measure", "B": "Daily oral preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine", "C": "Regular condom use without additional measures", "D": "Avoiding sexual activity altogether"}, "Answer": "B: Daily oral preexposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine. The best answer is B. This option is appropriate because daily oral PrEP has been proven to be safe and effective in reducing the risk of sexual HIV acquisition in adults at substantial risk, such as this patient. While regular testing and condom use are helpful, they do not offer the same robust risk reduction as PrEP does in this context."}, "context": "# Summary\nPreexposure Prophylaxis for HIV Prevention in the United States -2013: A Clinical Practice Guideline provides comprehensive information for the use of daily oral antiretroviral preexposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection in adults. The key messages of the guideline are as follows:\n\uf0a7 Daily oral PrEP with the fixed-dose combination of tenofovir disoproxil fumarate (TDF) 300 mg and emtricitabine (FTC) 200 mg has been shown to be safe and effective in reducing the risk of sexual HIV acquisition in adults; therefore, o PrEP is recommended as one prevention option for sexually-active adult MSM (men who have sex with men) at substantial risk of HIV acquisition (IA) 1 o PrEP is recommended as one prevention option for adult heterosexually active men and women who are at substantial risk of HIV acquisition. (IA) o PrEP is recommended as one prevention option for adult injection drug users (IDU) at substantial risk of HIV acquisition. (IA) o PrEP should be discussed with heterosexually-active women and men whose partners are known to have HIV infection (i.e., HIV-discordant couples) as one of several options to protect the uninfected partner during conception and pregnancy so that an informed decision can be made in awareness of what is known and unknown about benefits and risks of PrEP for mother and fetus (IIB) \uf0a7 Currently the data on the efficacy and safety of PrEP for adolescents are insufficient."}, {"Final_set": {"Context": "Pre-exposure prophylaxis (PrEP) is a prevention strategy for individuals at high risk of HIV infection. It is important that clinicians monitor renal function when prescribing PrEP, as renal failure can develop in certain patients. High adherence rates to the PrEP regimen significantly enhance its effectiveness, and it is essential for patients to be encouraged to combine PrEP with other preventative measures, such as behavioral risk-reduction strategies and condom use. Direct access to such services can improve outcomes for patients on PrEP therapy.", "Question": "What is the primary reason for clinicians to monitor renal function in patients prescribed Pre-exposure prophylaxis (PrEP)?", "Choices": {"A": "To ensure that the patient maintains a high level of medication adherence.", "B": "To prevent the development of renal failure that may occur during PrEP treatment.", "C": "To facilitate access to additional behavioral risk-reduction strategies.", "D": "To enhance the effectiveness of PrEP through combinational therapy."}, "Answer": "B: To prevent the development of renal failure that may occur during PrEP treatment. The rationale behind monitoring renal function is that certain individuals may experience renal impairment while on PrEP. By routinely assessing kidney function, clinicians can identify issues early and prevent the continuation of PrEP in patients at risk for worsening renal health. Adherence and effective risk-reduction services also contribute to overall prevention but are not the primary reason for renal monitoring."}, "context": "PrEP so that those in whom renal failure is developing do not continue to take it. (IIIA) \uf0a7 When PrEP is prescribed, clinicians should provide access, directly or by facilitated referral, to proven effective risk-reduction services. Because high medication adherence is critical to PrEP efficacy but was not uniformly achieved by trial participants, patients should be encouraged and enabled to use PrEP in combination with other effective prevention methods."}, {"Final_set": {"Context": "A 56-year-old man presents to the emergency department with severe chest pain radiating to his left arm. He states that the pain began abruptly while he was watching television and is associated with shortness of breath and sweating. His past medical history includes hypertension, hyperlipidemia, and a family history of coronary artery disease. On examination, his vital signs reveal a blood pressure of 150/90 mmHg, a heart rate of 105 bpm, and an oxygen saturation of 94%. An ECG shows ST-segment elevation in the anterior leads. The patient is diagnosed with an ST-elevation myocardial infarction (STEMI).", "Question": "What is the most appropriate initial management for this patient in the emergency department?", "Choices": ["A: Administer intravenous nitroglycerin for chest pain relief", "B: Begin thrombolytic therapy as soon as possible", "C: Perform coronary angiography immediately", "D: Initiate high-dose statin therapy"], "Answer": "B: Begin thrombolytic therapy as soon as possible. The best answer is B. In a patient with STEMI demonstrated by ST-segment elevation on ECG, early intervention is crucial to restore coronary blood flow. Thrombolytic therapy is most effective when administered as soon as possible after the onset of symptoms. While options A, C, and D may be part of the patient's overall management, thrombolytic therapy is the most critical initial treatment for this condition."}, "context": "(IIIA)"}, {"Final_set": {"Context": "Recent findings from several clinical trials have demonstrated safety and a substantial reduction in the rate of HIV acquisition for men who have sex with men (MSM), men and women in heterosexual HIV-discordant couples, and heterosexual men and women recruited as individuals who were prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with a fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). In addition, one clinical trial among injection drug users (IDU) and one among men and women in heterosexual HIV-discordant couples have demonstrated substantial efficacy and safety of daily oral PrEP with TDF alone. The demonstrated efficacy of PrEP was in addition to the effects of repeated condom provision, sexual risk-reduction counseling, and the diagnosis and treatment of sexually transmitted infection (STI), all of which were provided to trial participants, including those in the drug treatment group and those in the placebo group. In July 2012, after reviewing the available trial results, the U.S. Food and Drug Administration (FDA) approved an indication for the use of Truvada (TDF/FC) 'in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.'", "Question": "A 28-year-old man who has multiple sexual partners seeks to reduce his risk of acquiring HIV. He is interested in preventive measures he can take, specifically regarding medication. Which of the following options has been shown to significantly reduce the risk of HIV-1 acquisition in high-risk individuals?", "Choices": {"A": "Daily administration of tenofovir disoproxil fumarate (TDF) combined with emtricitabine (FTC)", "B": "Intermittent use of doxycycline as a pre-exposure prophylaxis", "C": "Monthly intramuscular injections of hormonal contraception", "D": "Daily vitamin supplementation to boost overall health"}, "Answer": "A: Daily administration of tenofovir disoproxil fumarate (TDF) combined with emtricitabine (FTC). The best answer is A. Numerous clinical trials have demonstrated that TDF/FTC, when taken daily as pre-exposure prophylaxis (PrEP), significantly reduces the risk of HIV acquisition in high-risk individuals, including men who have sex with men and individuals in HIV-discordant relationships. Other options listed do not have established efficacy for HIV prevention."}, "context": "# Introduction\nRecent findings from several clinical trials have demonstrated safety 1 and a substantial reduction in the rate of HIV acquisition for men who have sex with men (MSM) 2 , men and women in heterosexual HIV-discordant couples 3 , and heterosexual men and women recruited as individuals 4 who were prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with a fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). In addition, one clinical trial among injection drug users (IDU) 5 and one among men and women in heterosexual HIV-discordant couples 3 have demonstrated substantial efficacy and safety of daily oral PrEP with TDF alone. The demonstrated efficacy of PrEP was in addition to the effects of repeated condom provision, sexual risk-reduction counseling, and the diagnosis and treatment of sexually transmitted infection (STI), all of which were provided to trial participants, including those in the drug treatment group and those in the placebo group. In July 2012, after reviewing the available trial results, the U.S. Food and Drug Administration (FDA) approved an indication for the use of Truvada \u2020 (TDF/FC) \"in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk\" 6,7 ."}, {"Final_set": {"Context": "This publication provides a comprehensive clinical practice guideline for the use of PrEP for the prevention of HIV infection in the United States. It incorporates and extends information provided in interim guidance for PrEP use with MSM, with heterosexually active adults, and with IDU (also called persons who inject drugs). Currently, prescribing daily oral PrEP with TDF/FTC is recommended as one prevention option for MSM, heterosexual men, heterosexual women, and IDU at substantial risk of HIV acquisition. As the results of additional PrEP clinical trials and studies in these and other populations at risk of HIV acquisition become known, this guideline will be updated. The intended users of this guideline include primary care clinicians who provide care to persons at risk of acquiring HIV infection, clinicians who provide substance abuse treatment, infectious disease and HIV treatment specialists who may provide PrEP or serve as consultants to primary care physicians about the use of antiretroviral medications, and health program policymakers.", "Question": "A 28-year-old man who identifies as a gay male presents to his primary care physician to discuss options for preventing HIV infection. He is sexually active and has multiple partners. Which of the following is the most appropriate intervention to reduce his risk of HIV acquisition?", "Choices": {"A": "Encourage him to use condoms consistently and correctly during sexual encounters", "B": "Prescribe daily oral PrEP with TDF/FTC", "C": "Recommend abstinence from sexual activity", "D": "Suggest annual HIV testing without any other interventions"}, "Answer": "B: Prescribe daily oral PrEP with TDF/FTC. The best answer is B. This is the correct answer because PrEP, particularly with TDF/FTC, is specifically recommended for individuals at substantial risk of HIV acquisition, such as this patient who is a sexually active gay male with multiple partners. While condom use (option A) is important, daily PrEP provides an additional and effective layer of prevention that is appropriate for this individual based on current guidelines."}, "context": "This publication provides a comprehensive clinical practice guideline for the use of PrEP for the prevention of HIV infection in the United States. It incorporates and extends information provided in interim guidance for PrEP use with MSM 9 , with heterosexually active adults 10 , and with IDU (also called persons who injection drugs ) 11 . Currently, prescribing daily oral PrEP with TDF/FTC is recommended as one prevention option for MSM, heterosexual men, heterosexual women, and IDU at substantial risk of HIV acquisition. As the results of additional PrEP clinical trials and studies in these and other populations at risk of HIV acquisition become known, this guideline will be updated.\nThe intended users of this guideline include \uf0a7 primary care clinicians who provide care to persons at risk of acquiring HIV infection \uf0a7 clinicians who provide substance abuse treatment \uf0a7 infectious disease and HIV treatment specialists who may provide PrEP or serve as consultants to primary care physicians about the use of antiretroviral medications \uf0a7 health program policymakers."}, {"Final_set": {"Context": "In recent studies, the use of antiretroviral therapy for postexposure prophylaxis (PEP) has been shown to significantly reduce the risk of HIV acquisition. For instance, in healthcare workers exposed to HIV-infected blood, the administration of zidovudine within 72 hours and continued for 28 days reduced the risk of HIV infection by 81%. Moreover, pregnant HIV-infected women receiving zidovudine during labor and postpartum for their infants also demonstrated a substantial decrease in perinatal transmission of HIV. These findings support the effectiveness of antiretroviral medications in both postexposure and preexposure prophylaxis, leading to the implementation of clinical trials assessing the safety and efficacy of preexposure prophylaxis (PrEP) among high-risk populations.", "Question": "A 25-year-old man presents to the clinic seeking advice on preventing HIV infection. He is sexually active with multiple partners and is concerned about his risk. Which of the following strategies has been demonstrated to significantly reduce the risk of HIV infection when used prior to exposure?", "Choices": {"A": "Daily use of oral antiretroviral medication (PrEP)", "B": "Consistent use of condoms", "C": "Monthly testing for HIV", "D": "Post-exposure prophylaxis (PEP) after unprotected exposure"}, "Answer": "A: Daily use of oral antiretroviral medication (PrEP). The correct answer is A. PrEP has been proven effective in clinical trials to reduce the risk of acquiring HIV in individuals at high risk before they are exposed to the virus. Unlike PEP, which is utilized after the potential exposure has occurred, PrEP is proactive and taken daily to offer protection. While the other options have various levels of effectiveness in reducing HIV transmission, PrEP has demonstrated significant efficacy in randomized trials, particularly in populations with multiple exposure risks."}, "context": "# Evidence of the Safety and Efficacy of Antiretroviral Prophylaxis\nThe biological plausibility and the short-term safety of antiretroviral use to prevent HIV acquisition in other exposure situations have been demonstrated in 2 studies conducted prior to the PrEP trials. In a randomized placebo-controlled trial, perinatal transmission was reduced 68% among the HIV-infected women who received zidovudine during pregnancy and labor and whose infants received zidovudine for 6 weeks after birth 13 . That is, these infants received both preexposure and postexposure prophylaxis. In 1995, investigators used case-control surveillance data from health-care workers to demonstrate that zidovudine provided within 72 hours after percutaneous exposure to HIV-infected blood and continued for 28 days (PEP, or postexposure prophylaxis) was associated with an 81% reduction in the risk of acquiring HIV infection  .\nEvidence from these human studies of blood-borne and perinatal transmission as well as studies of vaginal and rectal exposure among animals  suggested that PrEP (using antiretroviral drugs) could reduce the risk of acquiring HIV infection from sexual and drug-use exposures. Clinical trials were launched to evaluate the safety and efficacy of PrEP in populations at risk of HIV infection through several routes of exposure. The results of completed trials published as of August 2013 are summarized below. See also Tables 2-6."}, {"Final_set": {"Context": "The IPREX trial (Pre-exposure Prophylaxis Initiative) was a clinical study aimed at evaluating the efficacy of pre-exposure prophylaxis (PrEP) with antiretroviral medication in preventing HIV transmission in high-risk populations. The trial demonstrated that daily use of PrEP could reduce the risk of acquiring HIV by more than 90% when taken consistently. Additionally, the study underscored the importance of ongoing risk assessment, adherence to medication, and regular follow-up for individuals using PrEP. Overall, IPREX significantly contributed to the understanding of HIV prevention strategies.", "Question": "A 25-year-old man who is at high risk for HIV infection is interested in starting pre-exposure prophylaxis (PrEP) to reduce his risk. He has heard about the recent IPREX trial and its findings. Which of the following statements about the IPREX trial findings is true?", "Choices": {"A": "The IPREX trial showed that PrEP is most effective when taken only as needed around the times of potential exposure.", "B": "The trial found that the efficacy of PrEP is significantly less when used inconsistently.", "C": "In the IPREX trial, PrEP was shown to be effective in reducing HIV acquisition by less than 50%.", "D": "The trial demonstrated that PrEP should be used only in combination with other antiretroviral therapies for it to be effective."}, "Answer": "B: The trial found that the efficacy of PrEP is significantly less when used inconsistently. The best answer is B. The IPREX trial highlighted that consistent adherence to PrEP is crucial for achieving its full protective effect, with studies showing that daily use reduces the risk of acquiring HIV by over 90%. Other options are incorrect; while PrEP can be effective, it requires consistent daily use rather than as-needed dosing (A), it was shown to have significant efficacy (C), and it is effective as a standalone prevention method without needing other antiretroviral therapies for efficacy (D)."}, "context": "# IPREX (PREEXPOSURE PROPHYLAXIS INITIATIVE) TRIAL"}, {"Final_set": {"Context": "The iPrEx study 2 was a phase 3, randomized, double-blind, placebo-controlled trial that evaluated the efficacy of a fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) in preventing HIV infection among men who have sex with men and male-to-female transgender individuals. Participants received a daily oral dose of TDF/FTC or placebo and were monitored every 4 weeks for interviews, HIV testing, and counseling. The study found that the TDF/FTC group had a 44% lower risk of acquiring HIV compared to the placebo group, a figure that increased with higher adherence levels. This data highlights the importance of adherence to PrEP (pre-exposure prophylaxis) medication in reducing the risk of HIV infection significantly.", "Question": "A 25-year-old man who engages in sexual intercourse with multiple partners seeks advice on reducing his risk of acquiring HIV. He is informed about the benefits of pre-exposure prophylaxis (PrEP) involving tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Which of the following factors is most likely associated with an increased efficacy of this PrEP regimen?", "Choices": ["A: Taking the PrEP medication with food", "B: Adherence to the daily dosing schedule", "C: Use of condoms during sexual intercourse", "D: Routine testing for sexually transmitted infections (STIs)"], "Answer": "B: Adherence to the daily dosing schedule. The correct answer is B because the study showed that increased adherence to the TDF/FTC regimen significantly correlated with greater reductions in HIV acquisition risk. It was noted that those with self-reported adherence of \u226590% experienced a 73% reduction in risk, emphasizing that consistent daily intake of the medication enhances its protective effects against HIV. Other measures, while beneficial, do not have the same direct correlation with the efficacy of the medication itself."}, "context": "The iPrEx study 2 was a phase 3, randomized, double-blind, placebo-controlled trial conducted in Peru, Ecuador, Brazil, Thailand, South Africa, and the United States among men and male-tofemale transgender adults who reported sex with a man during the 6 months preceding enrollment. Participants were randomly assigned to receive a daily oral dose of either the fixeddose combination of TDF and FTC or a placebo. All participants (drug and placebo groups) were seen every 4 weeks for an interview, HIV testing, counseling about risk-reduction and adherence to PrEP medication doses, pill count, and dispensing of pills and condoms. Analysis of data through May 1, 2010, revealed that after the exclusion of 58 participants (10 later determined to be HIV-infected at enrollment and 48 who did not have an HIV test after enrollment), 36 of 1,224 participants in the TDF/FTC group and 64 of 1,217 in the placebo group had acquired HIV infection. Enrollment in the TDF/FTC group was associated with a 44% reduction in the risk of HIV acquisition (95% CI, 15-63). The reduction was greater in the as-treated analysis: at the visits at which adherence was \u226550% (by self-report and pill count/dispensing), the reduction in HIV acquisition was 50% (95% CI, . The reduction in the risk of HIV acquisition was 73% at visits at which self-reported adherence was \u226590% (95% CI, 41-88) during the preceding 30 days. Among participants randomly assigned to the TDF/FTC group, plasma and intracellular drug-level"}, {"Final_set": {"Context": "In a clinical trial assessing the safety of a new medication for managing hypertension, it was found that participants experienced an increased incidence of adverse cardiovascular events compared to the control group. In addition to cardiovascular issues, some patients reported side effects such as dizziness and fatigue. The trial highlighted the importance of monitoring patients closely, especially during the initial dosing period. Given the potential risks, the trial concluded with recommendations for thorough patient education regarding the medication and follow-up visits to assess ongoing safety.", "Question": "A clinical trial evaluating a new antihypertensive medication found an increased incidence of adverse cardiovascular events among participants. What is the most critical recommendation for physicians when prescribing this medication based on the trial's findings?", "Choices": {"A": "Prescribing the medication only to patients without a history of cardiovascular disease", "B": "Scheduling follow-up visits to monitor cardiovascular health closely", "C": "Advising patients to discontinue medication if they experience dizziness", "D": "Reducing the initial dose to minimize side effects"}, "Answer": "B: Scheduling follow-up visits to monitor cardiovascular health closely. This is the best answer because the trial's increased incidence of cardiovascular events emphasizes the necessity of close monitoring to identify potential complications early in patients taking the medication. Regular follow-up visits are essential for assessing ongoing safety and effectiveness."}, "context": "# US MSM SAFETY TRIAL"}, {"Final_set": {"Context": "The US MSM Safety Trial 1 was a phase 2 randomized, double-blind, placebo-controlled study of the clinical safety and behavioral effects of TDF for HIV prevention among 400 MSM in San Francisco, Boston, and Atlanta. Participants were randomly assigned 1:1:1:1 to receive daily oral TDF or placebo immediately or after a 9-month delay. Participants were seen for follow-up visits 1 month after enrollment and quarterly thereafter. Among those without directed drug interruptions, medication adherence was high: 92% by pill count and 77% by pill bottle openings recorded by Medication Event Monitoring System (MEMS) caps. Temporary drug interruptions and the overall frequency of adverse events did not differ significantly between TDF and placebo groups. In multivariable analyses, back pain was the only adverse event associated with receipt of TDF. In a subset of men at the San Francisco site (n=184) for whom bone mineral density (BMD) was assessed, receipt of TDF was associated with small decrease in BMD (1% decrease at the femoral neck, 0.8% decrease for total hip). TDF was not associated with reported bone fractures at any anatomical site. Among 7 seroconversions, no HIV with mutations associated with TDF resistance was detected. No HIV infections occurred while participants were being given TDF; 3 occurred in men while taking placebo, 3 occurred among men in the delayed TDF group who had not started receiving drug; 1 occurred in a man who had been randomly assigned to receive.", "Question": "A 30-year-old man at high risk for HIV is considering pre-exposure prophylaxis (PrEP) to reduce his risk of acquiring the virus. Based on the results from a recent clinical trial assessing the safety of tenofovir disoproxil fumarate (TDF), which of the following is a potential concern for this patient while receiving TDF as PrEP?", "Choices": {"A": "Increased bone mineral density", "B": "Significant increase in fracture risk", "C": "Mild decrease in bone mineral density", "D": "Significant hepatotoxicity"}, "Answer": "C: Mild decrease in bone mineral density. The best answer is C. The clinical trial indicated that TDF usage was associated with a small decrease in bone mineral density, particularly at the femoral neck and total hip. However, no significant increase in fracture risk or other severe adverse events was noted, making the mild bone density decrease the most relevant concern for the patient while on TDF as PrEP."}, "context": "The US MSM Safety Trial 1 was a phase 2 randomized, double-blind, placebo-controlled study of the clinical safety and behavioral effects of TDF for HIV prevention among 400 MSM in San Francisco, Boston, and Atlanta. Participants were randomly assigned 1:1:1:1 to receive daily oral TDF or placebo immediately or after a 9-month delay. Participants were seen for follow-up visits 1 month after enrollment and quarterly thereafter. Among those without directed drug interruptions, medication adherence was high: 92% by pill count and 77% by pill bottle openings recorded by Medication Event Monitoring System (MEMS) caps. Temporary drug interruptions and the overall frequency of adverse events did not differ significantly between TDF and placebo groups. In multivariable analyses, back pain was the only adverse event associated with receipt of TDF. In a subset of men at the San Francisco site (n=184) for whom bone mineral density (BMD) was assessed, receipt of TDF was associated with small decrease in BMD (1% decrease at the femoral neck, 0.8% decrease for total hip) 20 . TDF was not associated with reported bone fractures at any anatomical site. Among 7 seroconversions, no HIV with mutations associated with TDF resistance was detected. No HIV infections occurred while participants were being given TDF; 3 occurred in men while taking placebo, 3 occurred among men in the delayed TDF group who had not started receiving drug; 1 occurred in a man who had been randomly assigned to receive"}, {"Final_set": {"Context": "Antiretroviral preexposure prophylaxis (PrEP) has been shown to significantly reduce the risk of HIV transmission in various populations. Randomized controlled trials have demonstrated the effectiveness of antiretroviral medications when taken consistently by individuals at high risk of HIV exposure. For heterosexual men and women, studies indicate that PrEP can lower the incidence of HIV by up to 99% when adherence is high. Despite its effectiveness, there remain discussions regarding accessibility, adherence challenges, and the importance of regular follow-up and testing for sexually transmitted infections (STIs) among PrEP users.", "Question": "A 28-year-old sexually active woman seeks counseling about preexposure prophylaxis (PrEP) to reduce her risk of HIV infection. She is in a monogamous relationship with a partner who has a known HIV-positive status but is on effective antiretroviral therapy. Which of the following statements regarding the use of PrEP in this scenario is true?", "Choices": {"A": "PrEP is unnecessary for the woman since her partner is on effective antiretroviral therapy and has an undetectable viral load.", "B": "The woman can benefit from PrEP as it can provide additional protection against HIV beyond her partner's treatment.", "C": "PrEP should only be prescribed if the woman experiences high-risk sexual behavior outside her current relationship.", "D": "The woman should wait to start PrEP until she has experienced a potential HIV exposure."}, "Answer": "B: The woman can benefit from PrEP as it can provide additional protection against HIV beyond her partner's treatment. This is the correct answer because while her partner's effective antiretroviral therapy significantly reduces the risk of HIV transmission, PrEP offers an added layer of protection which is especially important in high-risk scenarios. It is crucial for individuals engaged in relationships where one partner is HIV-positive to consider PrEP, even when the HIV-positive partner has an undetectable viral load, to maintain a high level of protection."}, "context": "# PUBLISHED TRIALS OF ANTIRETROVIRAL PREEXPOSURE PROPHYLAXIS AMONG HETEROSEXUAL MEN AND WOMEN"}, {"Final_set": {"Context": "The Partners PrEP trial was a phase 3 randomized, double-blind, placebo-controlled study designed to assess the efficacy of daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or tenofovir disoproxil fumarate (TDF) in preventing HIV acquisition among uninfected partners in HIV-discordant couples. Conducted with 4,758 participants from Uganda and Kenya, the trial demonstrated significant effectiveness of the antiretroviral medications compared to a placebo. Notably, 48% of couples had a male HIV-positive partner, and eligible HIV-positive partners had a median CD4 count of 495 cells/\u00b5L without receiving antiretroviral treatment as per local guidelines. The study included regular monitoring and follow-up, with medication discontinuation for women who became pregnant during the trial.", "Question": "What was the main outcome measure of the Partners PrEP trial regarding the use of TDF/FTC and TDF in HIV-discordant couples?", "Choices": {"A": "Changes in CD4 counts of HIV-positive partners", "B": "Incidence of HIV transmission to the uninfected partner", "C": "Rate of adverse effects from the medications", "D": "Number of couples who discontinued participation due to pregnancy"}, "Answer": "B: Incidence of HIV transmission to the uninfected partner. The main outcome measure of the Partners PrEP trial was to determine the effectiveness of the antiretroviral medications (TDF/FTC or TDF) in preventing HIV transmission from the infected partner to the uninfected partner in HIV-discordant couples. The statistically significant reduction of HIV acquisition among participants taking the medications compared to the placebo group highlights the primary goal of the study."}, "context": "# PARTNERS PREP TRIAL\nThe Partners PrEP trial 3,21 was a phase 3 randomized, double-blind, placebo-controlled study of daily oral TDF/FTC or TDF for the prevention of acquisition of HIV by the uninfected partner in 4,758 HIV-discordant heterosexual couples in Uganda and Kenya. The trial was stopped after an interim analysis in mid-2011 showed statistically significant efficacy in the medication groups (TDF/FTC or TDF) compared with the placebo group. In 48% of couples, the infected partner was male. HIV-positive partners had a median CD4 count of 495 cells/\u00b5L and were not being prescribed antiretroviral therapy because they were not eligible by local treatment guidelines. Participants had monthly follow-up visits and the study drug was discontinued among women who became pregnant during the trial."}, {"Final_set": {"Context": "Recent studies have suggested that certain lifestyle factors can influence the incidence of depression among adolescents. One report indicated that high levels of screen time, particularly for social media engagement, were positively correlated with increased symptoms of depression and anxiety. Concurrently, regular physical activity was associated with reduced depressive symptoms. Furthermore, psychosocial factors such as family support and peer relationships also play a crucial role in moderating mental health outcomes among teenagers.", "Question": "A 15-year-old adolescent presents to the clinic with symptoms of persistent sadness, fatigue, and a lack of interest in daily activities. The patient reports spending over 6 hours per day on social media and rarely engages in physical exercise. Which of the following interventions is most likely to improve the patient's depressive symptoms?", "Choices": {"A": "Increasing the patient's screen time to improve social engagement", "B": "Encouraging regular physical activity and reducing screen time", "C": "Referring the patient for group therapy focused on social media usage", "D": "Maintaining current lifestyle habits without any modifications"}, "Answer": "B: Encouraging regular physical activity and reducing screen time. The best answer is B. This response aligns with findings that suggest reducing screen time and increasing physical activity can lead to improvements in mental health, particularly reducing symptoms of depression among adolescents. Engaging in regular exercise can enhance mood and overall well-being, while excessive screen time, especially on social media, has been linked to increased depressive symptoms."}, "context": "(10.3 per 100 person -years) and rates did not differ significantly between the study groups."}, {"Final_set": {"Context": "Medication adherence by pill count was 84% in both groups. Nausea, vomiting, and dizziness occurred more commonly, primarily during the first month of use, among those randomly assigned to TDF/FTC than among those assigned to placebo. The groups did not differ in rates of serious clinical or laboratory adverse events. Pregnancy rates and rates of fetal loss did not differ by study group.", "Question": "A study examined the side effects of a new antiretroviral medication regimen compared to placebo in HIV-positive individuals. During the first month of treatment, patients receiving the active regimen reported more common adverse effects such as nausea and dizziness. Based on these findings, what might be the primary reason for this increased incidence of side effects?", "Choices": {"A": "The active medication has a higher incidence of drug-drug interactions.", "B": "Patients may have increased anxiety due to starting new medication.", "C": "The active regimen has a known profile of gastrointestinal intolerance.", "D": "Placebo effects reduce the reporting of side effects in the control group."}, "Answer": "C: The active regimen has a known profile of gastrointestinal intolerance. The best answer is C. The side effects of nausea and dizziness are often associated with certain antiretroviral regimens, indicating that the medication itself may have a chemical composition that causes these gastrointestinal disturbances. Additionally, the other options suggest factors that are less likely to be the main contributors to the specific side effects noted in this study."}, "context": "Medication adherence by pill count was 84% in both groups. Nausea, vomiting, and dizziness occurred more commonly, primarily during the first month of use, among those randomly assigned to TDF/FTC than among those assigned to placebo. The groups did not differ in rates of serious clinical or laboratory adverse events. Pregnancy rates and rates of fetal loss did not differ by study group."}, {"Final_set": {"Context": "The FEM-PrEP trial was a phase 3 randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of daily Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) for HIV prevention among heterosexual women in South Africa, Kenya, and Tanzania. The study faced challenges with adherence, as less than 50% of women had detectable levels of the study drug in plasma. The trial was halted due to an interim analysis indicating that it would unlikely demonstrate a significant efficacy difference between TDF/FTC and placebo. Notable adverse events reported among the TDF/FTC group included nausea and transient elevations in liver function tests, while no significant renal function changes were observed. The results revealed no significant reduction in HIV incidence, with a hazard ratio close to 1, and resistant virus detected in some participants.", "Question": "What is the primary reason for the termination of the FEM-PrEP trial?", "Choices": {"A": "High rates of adverse events among participants", "B": "Low adherence rates leading to insufficient data on efficacy", "C": "Significant reduction in HIV incidence compared to placebo", "D": "High pregnancy rates among participants receiving TDF/FTC"}, "Answer": "B: Low adherence rates leading to insufficient data on efficacy. The best answer is B because the trial was stopped after an interim analysis indicated that adherence was low, with <50% of women having detectable study drug levels. This low adherence would make it difficult to draw meaningful conclusions about the efficacy of TDF/FTC in reducing HIV incidence compared to placebo."}, "context": "# FEM-PREP TRIAL\nThe FEM-PrEP trial 23 was a phase 3 randomized, double-blind, placebo-controlled study of the HIV prevention efficacy and clinical safety of daily TDF/FTC among heterosexual women in South Africa, Kenya, and Tanzania. Participants were seen at monthly follow-up visits, and study drug was discontinued among women who became pregnant during the trial. The trial was stopped in 2011, when an interim analysis determined that the trial would be unlikely to detect a statistically significant difference in efficacy between the two study groups.\nAdherence was low in this trial: study drug was detected in plasma samples of <50% of women randomly assigned to TDF/FTC. Among adverse events, only nausea and vomiting (in the first month) and transient, modest elevations in liver function test values were more common among those assigned to TDF/FTC than those assigned to placebo. No changes in renal function were seen in either group. Initial analyses of efficacy results showed 4.7 infections per 100/ personyears in the TDF/FTC group and 5.0 infections per 100 person-years in the placebo group. The hazard ratio 0.94 (95% CI, 0.59-1.52) indicated no reduction in HIV incidence associated with TDF/FTC use. Of the 68 women who acquired HIV infection during the trial, TDF or FTC resistant virus was detected in 5 women: 1 in the placebo group and 4 in the TDF/FTC group. In multivariate analyses, there was no association between pregnancy rate and study group."}, {"Final_set": {"Context": "The VOICE (Vaginal and Oral Interventions to Control the Epidemic) trial was a phase 2B randomized, double-blind study designed to evaluate the effectiveness of oral and topical antiretroviral regimens among heterosexual women in eastern and southern Africa. The study's primary goal was to assess the HIV prevention efficacy of daily oral medications (TDF or TDF/FTC) and a topical vaginal formulation (tenofovir) compared to their corresponding placebos. Interim analyses revealed no significant effectiveness for either the oral TDF or the TDF/FTC groups, leading to early termination of the groups receiving oral TDF and topical tenofovir due to futility. 52, 61, and 60 incident HIV infections were documented in the oral TDF, TDF/FTC, and placebo groups, respectively, implying that neither oral regimen demonstrated a significant reduction in HIV incidence.", "Question": "In a phase 2B clinical trial assessing HIV prevention methods among women, both oral TDF/FTC and oral TDF showed no significant efficacy in reducing HIV infections compared to placebo. Given that the TDF and TDF/FTC regimens were deemed ineffective, what could be a potential explanation for these results related to adherence to the medication?", "Choices": {"A": "High adherence rates among participants were observed during the trial.", "B": "Participants demonstrated a consistent misunderstanding of the medication regimen.", "C": "There may have been systematic issues in pill taking behavior over time.", "D": "Participants were highly motivated to prevent HIV infection."}, "Answer": "C: There may have been systematic issues in pill taking behavior over time. The best answer is C, as it reflects a common challenge in adherence studies, especially in long-term trials. Despite being assigned to an effective intervention, if participants did not maintain adherence to the medication regimen, it would result in no significant reductions in HIV infections. This highlights how crucial patient compliance is in the effectiveness of prophylactic treatments like TDF/FTC."}, "context": "# VOICE (VAGINAL AND ORAL INTERVENTIONS TO CONTROL THE EPIDEMIC) TRIAL\nVOICE (MTN-003) 25 was a phase 2B randomized, double-blind study comparing oral (TDF or TDF/FTC) and topical vaginal (tenofovir) antiretroviral regimens against corresponding oral and topical placebos among 5,029 heterosexual women enrolled in eastern and southern Africa. Of these women, 3,019 were randomly assigned to daily oral medication (TDF/FTC, 1,003; TDF, 1,007; oral placebo, 1,009). In 2011, the trial group receiving oral TDF and the group receiving topical tenofovir were stopped after interim analyses determined futility 26 . The group receiving oral TDF/FTC continued to the planned trial conclusion.\nAfter the exclusion of 15 women later determined to have had acute HIV infection when enrolled in an oral medication group and 27 with no follow-up visit after baseline, 52 incident HIV infections occurred in the oral TDF group, 61 in the TDF/FTC group, and 60 in the oral placebo group. Effectiveness was not significant for either oral PrEP medication group; \u221249%% for TDF (hazard ratio  1.49; 95% CI, 0.97-2.29) and \u22124.4% for TDF/FTC (HR, 1.04; 95% CI, 0.73-1.49) in the modified-intent-to-treat analysis."}, {"Final_set": {"Context": "The number of confirmed cases of elevated creatinine levels was more significant in patients taking oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) than in those receiving a placebo. However, other safety outcomes did not show significant differences between the TDF/FTC group and the placebo group. In a subgroup of women who had undetected acute HIV infections, two from the TDF/FTC group had the M184I/V mutation linked with FTC resistance, while one woman who acquired HIV after enrollment had a virus with the same mutation. Importantly, none of the participants with HIV had mutations associated with resistance to tenofovir. Despite challenges in determining efficacy due to varying adherence rates in multiple trials, substantial evidence from two trials indicates that daily oral PrEP with TDF/FTC is effective and safe for heterosexual men and women at high risk of HIV acquisition, particularly when adherence to the medication is high.", "Question": "A 28-year-old woman presents to a clinic seeking guidance on HIV prevention strategies. She is sexually active with multiple partners and expresses concern about her risk of HIV infection. After discussing options, the provider recommends daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Which of the following statements about this treatment is true?", "Choices": ["A: TDF/FTC PrEP has a high rate of mutations conferring resistance to both drugs in users.", "B: TDF/FTC is recommended only for individuals with a confirmed HIV diagnosis.", "C: High adherence to TDF/FTC has been associated with significant efficacy in preventing HIV infection.", "D: TDF/FTC has shown consistently significant differences in safety outcomes compared to placebo."], "Answer": "C: High adherence to TDF/FTC has been associated with significant efficacy in preventing HIV infection. This is the correct answer because the trials supporting TDF/FTC as PrEP showed substantial evidence of its efficacy particularly with high adherence rates. The other options are incorrect; A misrepresents the resistance mutations, B is false as it is for those at risk but not infected, and D incorrectly states the safety outcome differences between the groups."}, "context": "The number of confirmed creatinine elevations (grade not specified) observed was higher in the oral TDF/FTC group than in the oral placebo group. However, there were no significant differences between active product and placebo groups for other safety outcomes. Of women determined after enrollment to have had acute HIV infection at baseline, two women from the TDF/FTC group had virus with the M184I/V mutation associated with FTC resistance. One woman in the TDF/FTC group who acquired HIV infection after enrollment had virus with the M184I/V mutation; No participants with HIV infection had virus with a mutation associated with tenofovir resistance.\nIn summary, although low adherence and operational issues precluded reliable conclusions regarding efficacy in 3 trials (VOICE, FEM-PrEP and the West African trial) 27 , 2 trials (Partners PrEP and TDF2) with high medication adherence have provided substantial evidence of efficacy among heterosexual men and women. All 5 trials have found PrEP to be safe for these populations.\nDaily oral PrEP with TDF/FTC is recommended as one HIV prevention option for heterosexually-active men and women at substantial risk of HIV acquisition because these trials present evidence of its safety and 2 present evidence of efficacy in these populations, especially when medication adherence is high. (IA)."}, {"Final_set": {"Context": "The Bangkok Tenofovir Study (BTS) was a phase 3 randomized, double-blind, placebo-controlled trial aimed at assessing the safety and efficacy of daily oral Tenofovir Disoproxil Fumarate (TDF) for HIV prevention among injection drug users (IDUs) in Bangkok, Thailand. A total of 2,413 participants were enrolled, with 22% receiving methadone treatment at baseline. Participants could choose between a 28-day supply of pills or directly-observed therapy at their monthly visits. The study provided comprehensive services, including the distribution of condoms, bleach for cleaning injection equipment, methadone, primary medical care, and social services. The mean follow-up period was approximately 4.6 years, and participants received directly-observed therapy 87% of the time.", "Question": "In a clinical trial assessing the efficacy of Tenofovir Disoproxil Fumarate for HIV prevention among injection drug users, which of the following strategies would most likely enhance adherence to the therapy regimen in this population?", "Choices": {"A": "Providing economic incentives for consistent pill intake", "B": "Offering direct medical supervision of therapy", "C": "Distributing educational materials on HIV and drug abuse", "D": "Implementing a web-based monitoring system for medication adherence"}, "Answer": "B: Offering direct medical supervision of therapy. The best answer is B. Directly observed therapy (DOT) is known to significantly enhance medication adherence among populations with high-risk behaviors, as it provides support and supervises the intake of medication. In the context of the Bangkok Tenofovir Study, 87% of participants received therapy through a directly-observed method, which likely improved adherence and consequently increased the effectiveness of HIV prevention efforts among injection drug users."}, "context": "# BANGKOK TENOFOVIR STUDY (BTS)\nBTS 5 was a phase 3 randomized, double-blind, placebo-controlled study of the safety and efficacy of daily oral TDF for HIV prevention among 2,413 IDUs in Bangkok, Thailand. The study was conducted at drug treatment clinics; 22% of participants were receiving methadone treatment at baseline. At each monthly visit, participants could choose to receive either a 28-day supply of pills or to receive medication daily by directly-observed therapy. Study clinics (n=17) provided condoms, bleach (for cleaning injection equipment), methadone, primary medical care, and social services free of charge. Participants were followed for 4.6 years (mean) and received directly-observed therapy 87% of the time."}, {"Final_set": {"Context": "Rates of nausea and vomiting were higher among TDF than among placebo recipients in the first 2 months of medication but not thereafter. The rates of adverse events, deaths, or elevated creatinine did not differ significantly between the TDF and the placebo groups. Among the 49 HIV infections for which viral RNA could be amplified (of 50 incident infections and 2 infections later determined to have been present at enrollment), no virus with mutations associated with TDF resistance were identified. Among participants with HIV infection followed up for a maximum of 24 months, HIV plasma viral load was lower in the TDF than in the placebo group at the visit when HIV infection was detected (P = .01), but not thereafter (P = .10). Daily oral PrEP with TDF/FTC (or TDF alone) is recommended as one HIV prevention option for IDUs at substantial risk of HIV acquisition because this trial presents evidence of the safety and efficacy of TDF as PrEP in this population, especially when medication adherence is high. (IA)", "Question": "A 30-year-old intravenous drug user is seeking advice on HIV prevention strategies, as he believes he is at significant risk for HIV acquisition. He learns about pre-exposure prophylaxis (PrEP) using TDF/FTC. Which of the following statements is true regarding TDF as PrEP based on recent studies?", "Choices": ["A: TDF is effective only during the first month of therapy.", "B: TDF has been associated with significant rates of renal toxicity.", "C: The use of TDF has demonstrated a reduction in HIV plasma viral load at the time of infection detection.", "D: The efficacy of TDF decreases with prolonged use beyond 2 months."], "Answer": "C: The use of TDF has demonstrated a reduction in HIV plasma viral load at the time of infection detection. This answer is correct because the studies indicate that TDF was associated with a lower HIV plasma viral load at the time of infection detection compared to the placebo group, which supports the efficacy of TDF as a preventive measure in at-risk populations. The other statements are incorrect as TDF has a sustained efficacy beyond just the initial months, is not primarily associated with high rates of renal toxicity in this context, and the efficacy does not diminish after two months."}, "context": "Rates of nausea and vomiting were higher among TDF than among placebo recipients in the first 2 months of medication but not thereafter. The rates of adverse events, deaths, or elevated creatinine did not differ significantly between the TDF and the placebo groups. Among the 49 HIV infections for which viral RNA could be amplified (of 50 incident infections and 2 infections later determined to have been present at enrollment), no virus with mutations associated with TDF resistance were identified. Among participants with HIV infection followed up for a maximum of 24 months, HIV plasma viral load was lower in the TDF than in the placebo group at the visit when HIV infection was detected (P = .01), but not thereafter (P = .10).\nDaily oral PrEP with TDF/FTC (or TDF alone) is recommended as one HIV prevention option for IDUs at substantial risk of HIV acquisition because this trial presents evidence of the safety and efficacy of TDF as PrEP in this population, especially when medication adherence is high. (IA)"}, {"Final_set": {"Context": "# ASSESSING RISK OF SEXUAL HIV ACQUISITION\nBecause offering PrEP is currently indicated for MSM at substantial risk of HIV acquisition, it is important to consider that although 76% of MSM surveyed in 2008 in 21 US cities reported a health care visit during the past year, other studies reported that health care providers do not ask about, and patients often do not disclose, same-sex behaviors. Box A1 contains a set of brief questions designed to identify men who are currently having sex with men and to assess a key set of sexual practices that are associated with the risk of HIV acquisition. In studies to develop scored risk indexes predictive of incident HIV infection among MSM, several critical factors were identified.", "Question": "A 25-year-old man presents to his primary care provider for a routine check-up. He reports having multiple sex partners in the past year, including both male and female partners. He expresses concern about his risk for HIV, especially given that he has not been tested in over a year. Which of the following factors is most likely to increase his risk of acquiring HIV?", "Choices": {"A": "Consistent use of condoms with all partners", "B": "Having regular health care check-ups", "C": "Engaging in unprotected anal sex with multiple male partners", "D": "Being in a monogamous relationship with a lower-risk partner"}, "Answer": "C: Engaging in unprotected anal sex with multiple male partners. The best answer is C. This scenario highlights that certain sexual practices significantly increase the risk of HIV acquisition, particularly for men who have sex with men (MSM). Unprotected anal intercourse is known to be a high-risk behavior for transmitting HIV. Despite regular health check-ups and consistent condom use with all partners reducing risk, the presence of multiple male partners and lack of protection present a substantial risk for HIV acquisition."}, "context": "# ASSESSING RISK OF SEXUAL HIV ACQUISITION\nBecause offering PrEP is currently indicated for MSM at substantial risk of HIV acquisition, it is important to consider that although 76% of MSM surveyed in 2008 in 21 US cities reported a health care visit during the past year 34 , other studies reported that health care providers do not ask about, and patients often do not disclose, same-sex behaviors 35 .\nBox A1 contains a set of brief questions designed to identify men who are currently having sex with men and to assess a key set of sexual practices that are associated with the risk of HIV acquisition. In studies to develop scored risk indexes predictive of incident HIV infection among MSM 36,37 (see Providers' Supplement, Section 5), several critical factors were identified.\nBOX A1: RISK BEHAVIOR ASSESSMENT FOR MSM 36 Box A2 contains a set of brief questions designed to identify women and men who are currently having sex with opposite-sex partners (heterosexually active) and to assess a key set of sexual practices that are associated with the risk of HIV acquisition as identified both in PrEP trials and epidemiologic studies  .\nIn the past 6 months:"}, {"Final_set": {"Context": "In HIV prevention strategies, clinicians are encouraged to thoroughly assess the sexual risk behaviors of sexually active patients. For both heterosexual men and women, a recent diagnosis of bacterial sexually transmitted infections (STIs) such as chlamydia, syphilis, or gonorrhea could indicate heightened risk of HIV exposure. Additionally, sex without consistent condom use may be inferred from indicators such as a recent pregnancy in a female patient or her male partner. Clinicians should also routinely screen for substance use, particularly alcohol and non-injection drugs, as these can influence sexual decision-making and health metrics pertinent to HIV prevention and treatment adherence.", "Question": "A 28-year-old sexually active woman presents to a primary care clinic for an annual check-up. She discloses that she experienced a recent episode of chlamydia treated 2 months ago and has been using condoms inconsistently with her new partner. During the visit, she expresses concerns about preventing HIV. Which of the following factors is most relevant for the clinician to assess in order to tailor an effective prevention plan for this patient?", "Choices": {"A": "The patient\u2019s previous history of mental health disorders", "B": "The frequency of her current partner's sexual activities with others", "C": "The patient's travel history to countries with high HIV prevalence", "D": "The regularity of the patient's sleep patterns"}, "Answer": "B: The frequency of her current partner's sexual activities with others. This is the correct answer because knowing the sexual history of the patient's partner is critical for assessing the risk of potential HIV exposure. If her partner is sexually active with multiple partners without consistent condom use, this could significantly increase her risk of HIV. Understanding this context allows the clinician to provide appropriate recommendations for prevention strategies, such as PrEP and consistent condom use."}, "context": "# BOX A2: RISK BEHAVIOR ASSESSMENT FOR HETEROSEXUAL MEN AND WOMEN\nIn addition, for all sexually active patients, clinicians may want to consider reports of diagnoses of bacterial STIs (chlamydia, syphilis, gonorrhea) during the past 6 months as evidence of sexual activity that could result in HIV exposure. For heterosexual women and men, sex without a condom (or its correct use) may also be indicated by recent pregnancy of a female patient or sexual partner of a male patient.\nClinicians should also briefly screen all patients for alcohol abuse 41 (especially before sexual activity) and the use of illicit non-injection drugs (e.g., amyl nitrite, stimulants). 42,43 The use of these substances may affect sexual risk behavior 44 , hepatic or renal health, or medication adherence, any of which may affect decisions about the appropriateness of prescribing PrEP medication. In addition, if substance abuse is reported, the clinician should provide referral for appropriate treatment or harm-reduction services acceptable to the patient."}, {"Final_set": {"Context": "In the past 6 months, it is critical to assess an individual's sexual behaviors and practices when evaluating their risk for HIV infection. Key inquiries include whether the individual has had sexual relations with men, women, or both, as well as the number of partners involved. Taking note of instances when vaginal or anal intercourse occurred without a condom and determining the HIV status of partners is essential. Consistent condom use has been linked to an 80% reduction in HIV acquisition among heterosexual couples, while inconsistent usage is far less effective. In men who have sex with men (MSM) and other sexually active populations, studies show low recent rates of consistent condom use. Individuals should be counseled on the importance of discussing HIV status with partners and testing for those considered at risk, especially if they are unaware of a partner's HIV status.", "Question": "A 25-year-old man visits his healthcare provider for an annual check-up. He reports having multiple new sexual partners over the past six months, with inconsistent condom use, and is unaware of the HIV status of most of these partners. Considering his sexual history, what should the healthcare provider recommend to this patient in terms of HIV prevention?", "Choices": {"A": "Only encourage using condoms during sexual activity moving forward.", "B": "Discuss the option of pre-exposure prophylaxis (PrEP) while continuing to promote condom use.", "C": "Recommend routine HIV testing but advise that no additional prevention methods are necessary.", "D": "Advise the patient to refrain from all sexual activity until his partners are tested for HIV."}, "Answer": "B: Discuss the option of pre-exposure prophylaxis (PrEP) while continuing to promote condom use. This is the best answer because it addresses the patient's risk of HIV due to inconsistent condom use and the unknown HIV status of his partners. Offering PrEP alongside promoting condoms provides a comprehensive approach to reducing his risk of HIV acquisition. This is particularly important for individuals who engage in risky sexual behaviors, and PrEP can serve as an effective additional prevention method."}, "context": "# In the past 6 months:\n\uf0a7 Have you had sex with men, women, or both? \uf0a7 (if opposite sex or both sexes) How many men/women have you had sex with? \uf0a7 How many times did you have vaginal or anal sex when neither you nor your partner wore a condom? \uf0a7 How many of your sex partners were HIV-positive? \uf0a7 (if any positive) With these HIV-positive partners, how many times did you have vaginal or anal sex without a condom?\nReported consistent (\"always\") condom use is associated with an 80% reduction in HIV acquisition among heterosexual couples 48 . However, inconsistent condom use is less effective, 37,49 and studies have reported low rates of recent consistent condom use among MSM 50 and other sexually active adults 51 . Especially low rates have been reported when condom use was measured over several months rather than during most recent sex or the past 30 days 52 . Therefore, unless the patient reports confidence that consistent condom use can be achieved, additional HIV prevention methods, including the consideration of PrEP should be provided while continuing to support condom.\nA patient who reports that 1 or more regular sex partners is of unknown HIV status should be offered HIV testing for those partners, either in the clinician's practice or at a confidential testing site (see zip code lookup at /)."}, {"Final_set": {"context": "Clinicians should be vigilant in detecting signs and symptoms of illicit drug use in their patients, especially against the backdrop of the ongoing opioid crisis. While there is no recommendation for universal screening for illicit drug use, specific assessments should be conducted for those at high risk, such as individuals with a history of injected drug use. Understanding patients' current engagement with drug treatment programs is essential in providing comprehensive care. Sampling practices can be linked to health threats including but not limited to HIV, hepatitis B and C, and endocarditis. Thus, it is recommended to integrate HIV prevention measures with treatment and social support services for individuals who use injection drugs.", "question": "A 28-year-old man presents to the emergency department with concerns about recent health deterioration. He has a history of heroin use and has recently been sober for 3 months, attending weekly support meetings. However, he reports experiencing anxiety and urges to use again. What is the most appropriate next step in managing this patient?", "choices": {"A": "Initiate an opioid agonist therapy to manage cravings", "B": "Refer the patient to cognitive behavioral therapy immediately", "C": "Conduct a thorough screening for potential co-occurring mental health disorders", "D": "Suggest continued attendance to support groups and provide reassurance"}, "answer": "C: Conduct a thorough screening for potential co-occurring mental health disorders. The best answer is C. This approach integrates the understanding that anxiety and urges may stem from underlying mental health issues, and addressing these can improve treatment outcomes and support sustained recovery. This screening can help tailor further interventions, whether they include therapy, medication management, or increasing support services appropriate for the patient's individual needs."}, "context": "Although current evidence is insufficient for a recommendation that all patients be screened for injection or other illicit drug use, the US Preventive Services Task Force recommends that clinicians be alert to the signs and symptoms of illicit drug use in patients. 26 Clinicians should determine whether patients who are currently using illicit drugs are in (or want to enter) behavioral, medication-assisted, or in-patient drug treatment. For persons with a history of injecting illicit drugs but who are currently not injecting, clinicians should assess the risk of relapse along with the patients' use of relapse prevention services (e.g., a drug-related behavioral support program, use of mental health services, 12-step program).\nBox A3 contains a set of brief questions that may help identify persons who are injecting illicit drugs, and to assess a key set of injection practices that are associated with the risk of HIV acquisition as identified in the PrEP trial with IDU 5 and in epidemiologic studies 56,58 . PrEP or other HIV prevention should be integrated with prevention and clinical care services for the many health threats IDU may face (e.g., hepatitis B and C infection, abscesses, septicemia, endocarditis, overdose) 59 . In addition, referrals for drug treatment, mental health services, and social services may be indicated 59 ."}, {"Final_set": {"Context": "HIV testing and the documentation of results are required to confirm that patients do not have HIV infection when they start taking PrEP medications. For patient safety, HIV testing should be repeated at least every 3 months (before prescriptions are refilled or reissued). This requirement should be explained to patients during the discussion about whether PrEP is appropriate for them. The Centers for Disease Control and Prevention (CDC) and the US Preventive Services Task Force recommends that MSM, IDUs, patients with a sex partner who has HIV infection, and others at substantial risk of HIV acquisition undergo an HIV test at least annually. Additionally, specific questions should be asked to evaluate potential risks, such as drug usage and treatment programs.", "Question": "A 28-year-old man who identifies as a gay man visits a primary care clinic to discuss starting pre-exposure prophylaxis (PrEP) for HIV prevention. During his evaluation, which of the following should be part of the initial assessment to determine his suitability for PrEP?", "Choices": {"A": "A biopsy of lymph nodes to check for HIV", "B": "An HIV test to confirm he is HIV-negative", "C": "A chest X-ray to evaluate for opportunistic infections", "D": "A financial assessment to evaluate insurance coverage for PrEP"}, "Answer": "The correct answer is B: An HIV test to confirm he is HIV-negative. This is essential to ensure the safety of the patient before starting PrEP, as being HIV-positive contraindicates its use. It's important to establish his HIV status before initiating PrEP, and this requires documentation of the results. Options A, C, and D are not standard requirements for the initial evaluation of a patient considering PrEP. A lymph node biopsy and chest X-ray would not directly assess HIV status, while insurance assessment does not relate to medical evaluation for PrEP eligibility."}, "context": "# HIV TESTING\nHIV testing and the documentation of results are required to confirm that patients do not have HIV infection when they start taking PrEP medications. For patient safety, HIV testing and should be repeated at least every 3 months (before prescriptions are refilled or reissued). This requirement should be explained to patients during the discussion about whether PrEP is appropriate for them.\nThe Centers for Disease Control and Prevention (CDC) and the US Preventive Services Task Force recommends that MSM, IDUs, patients with a sex partner who has HIV infection, and others at substantial risk of HIV acquisition undergo an HIV test at least annually or for those \uf0a7 Have you ever injected drugs that were not prescribed to you by a clinician? \uf0a7 (if yes), When did you last inject unprescribed drugs? \uf0a7 In the past 6 months, have you injected by using needles, syringes, or other drug preparation equipment that had already been used by another person? \uf0a7 In the past 6 months, have you been in a methadone or other medication-based drug treatment program?\n\uf0a7 Adult person \uf0a7 Without acute or established HIV infection \uf0a7 Any injection of drugs not prescribed by a clinician in past 6 months AND at least one of the following \uf0a7 Any sharing of injection or drug preparation equipment in past 6 months \uf0a7 Been in a methadone, buprenorphine, or suboxone treatment program in past 6 months \uf0a7 Risk of sexual acquisition (also evaluate by criteria in Box B1 or B2)"}, {"Final_set": {"Context": "During a clinical trial evaluating the efficacy of pre-exposure prophylaxis (PrEP) for HIV, researchers noted that some participants had unrecognized acute HIV infections at enrollment. Two of these participants presented with drug-resistant strains of the virus after starting TDF/FTC (tenofovir disoproxil fumarate/emtricitabine) therapy. Symptoms consistent with a viral illness were reported by the majority of those with acute infections, despite negative initial antibody test results. Mutation analysis revealed the presence of the M184V/I mutation in these patients, indicating resistance to emtricitabine, but not the K65R mutation associated with resistance to tenofovir. These occurrences highlight the importance of HIV testing before starting PrEP and monitoring for acute infections.", "Question": "A 25-year-old male who identifies as a man who has sex with men (MSM) seeks to start PrEP for HIV prevention. During his initial visit, laboratory tests are performed, and he has negative HIV antibody results. However, he later reports symptoms of acute viral infection. If he began taking TDF/FTC prior to confirmation of his HIV status, which mutation might be expected if he is ultimately diagnosed with acute HIV?", "Choices": {"A": "K65R mutation associated with tenofovir resistance", "B": "M184V/I mutation associated with emtricitabine resistance", "C": "A mutation related to integrase inhibitors", "D": "No mutations would be present"}, "Answer": "B: M184V/I mutation associated with emtricitabine resistance. This is the correct answer because if the patient is diagnosed with acute HIV infection after having started TDF/FTC treatment without recognizing his infection, he may develop the M184V/I mutation. This mutation is specifically associated with resistance to emtricitabine, which is one of the components of the PrEP regimen. Thus, given the scenario of unrecognized acute infection and starting PrEP, it's likely that this patient would develop the emtricitabine resistance mutation."}, "context": "# ACUTE HIV INFECTION\nIn the iPrEx trial, drug-resistant virus developed in 2 persons with unrecognized acute HIV infection at enrollment and for whom TDF/FTC had been dispensed. These participants had negative antibody test results before they started taking PrEP, tested positive at a later study visit, and PCR (polymerase chain reaction) on stored specimens from the initial visit detected the presence of virus. When questioned, most of the 10 acutely infected participants (8 of whom had been randomly assigned the placebo group) reported signs and symptoms consistent with a viral syndrome 2 . Both acutely infected patients to whom TDF/FTC had been dispensed had the M184V/I mutation associated with emtricitabine resistance, but not the K65R mutation associated with tenofovir resistance 2 . Among participants who were dispensed PrEP medication in the US MSM Safety Trial and in the Partners PrEP, TDF2, and VOICE trials (see Table 6), the M184V mutation, developed in several persons who were enrolled and had started taking medication with unrecognized acute HIV infection but K65R developed in only one (in the TDF2 study). However, no mutations emerged in persons who acquired infection after baseline.\nIn the one trial with very low medication adherence that has published its resistance testing results, the emtricitabine resistance mutation, but not the K65R mutation was found in a few persons with incident infection after baseline (4 persons in the FEM-PrEP trial)."}, {"Final_set": {"Context": "Sexually active adults, particularly men who have sex with men (MSM), and those who use injectable drugs, are at a greater risk for hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. Screening for these infections is advisable before initiating pre-exposure prophylaxis (PrEP) with TDF/FTC. Vaccination against HBV is recommended for all adolescents and adults, especially for those at heightened risk, such as MSM. Both TDF and FTC are effective against HBV, and if a patient with HBV infection discontinues these medications, there is a significant risk of HBV reactivation, which could lead to liver damage.", "Question": "A 28-year-old man who identifies as gay comes to the clinic for PrEP initiation. He has no significant past medical history and is sexually active with multiple partners. He has not been vaccinated for hepatitis B and admits to occasional recreational drug use, including methamphetamine. Before initiating PrEP, which of the following steps is most crucial for this patient?", "Choices": {"A": "Initiate vaccination for hepatitis C prior to prescribing TDF/FTC", "B": "Obtain serological testing for HBV and HCV infections", "C": "Refer the patient to a substance abuse counselor", "D": "Schedule a follow-up appointment in one month to monitor side effects"}, "Answer": "B: Obtain serological testing for HBV and HCV infections. The correct answeris B, because screening for HBV and HCV is essential before starting PrEP with TDF/FTC in high-risk populations. This step ensures that the patient's current infection status is known, allowing for appropriate management. If the patient is found to be infected with HBV, initiating PrEP without the necessary precautions could lead to potential reactivation of the virus if the medication is discontinued later."}, "context": "# Optional adjustment of high actual body weight 71\nUsed only if the actual body weight is 30% greater than the IBW. Otherwise, the IBW is used.\n\n# HEPATITIS SEROLOGY\nSexually active adults (especially MSM), and persons who inject illicit drugs, are at risk of acquiring HBV infection 74 and hepatitis C virus (HCV) infection 75 . Vaccination against HBV is recommended for all adolescents and adults, especially for MSM 76 . Therefore, HBV and HCV infection status should be documented by screening serology before TDF/FTC is prescribed as PrEP (see Table 8). Those patients determined to be susceptible to HBV infection should be vaccinated.\nIn addition, both TDF and FTC are active against HBV. This has 2 implications for PrEP use. First, if patients with active HBV infection stop taking these medications, liver function must be closely monitored because reactivated HBV infection can result in hepatic damage 77 . In addition, a recent study demonstrated a lower rate of incident HBV infections among HIV-infected MSM whose treatment regimens included TDF or lamivudine (closely related to FTC) than among men whose regimens did not contain these drugs (0.7 vs 6.7 infections per 100 person-years). 78\n\n# Providing PrEP"}, {"Final_set": {"Context": "For individuals at risk for HIV transmission, pre-exposure prophylaxis (PrEP) is a highly effective preventive strategy. The fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) has been shown to significantly reduce the risk of contracting HIV when taken consistently. The recommended regimen includes taking this combination once daily for those who are at high risk, including men who have sex with men (MSM), heterosexually active individuals, and people who inject drugs (IDU). While TDF alone has shown efficacy, particularly among IDU and heterosexually active populations, its effectiveness in MSM has not been established due to a lack of trial data.", "Question": "A 26-year-old man who is sexually active with multiple partners comes to a clinic seeking advice on how to reduce his risk of contracting HIV. He has heard about pre-exposure prophylaxis (PrEP) but is unsure about its effectiveness. Which of the following is the most appropriate recommendation for this patient?", "Choices": {"A": "He should start taking tenofovir disoproxil fumarate (TDF) alone as PrEP.", "B": "He should use a fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for PrEP.", "C": "He should engage in regular testing for HIV and use condoms exclusively without PrEP.", "D": "He should consider starting antiretroviral therapy (ART) if he has a known HIV-positive partner."}, "Answer": "B: He should use a fixed-dose combination of tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) for PrEP. The reasoning is that the combination of TDF and FTC has been proven safe and effective for preventing HIV infection in at-risk populations, including MSM. While TDF alone is an option for some groups, it has not been effectively tested in MSM specifically, making the combination the preferred choice."}, "context": "# INDICATED MEDICATION\nThe medication proven safe and effective, and currently approved by FDA for PrEP in healthy adults at risk of acquiring HIV infection, is the fixed-dose combination of TDF and FTC in a single daily dose (see Table 9). Therefore, TDF/FTC is the recommended medication that should be prescribed for PrEP for MSM, heterosexually active men and women, and IDU who meet recommended criteria. Because TDF alone has been proven effective in trials with IDU and heterosexually active men and women, it can be considered as an alternative regimen for these specific populations. As PrEP for MSM, TDF alone is not recommended because no trials have been done, so the efficacy of TDF alone for MSM is unknown. In addition to the safety data obtained in PrEP clinical trials, data on drug interactions and longer-term toxicities have been obtained by studying the component drugs individually for their use in treatment of HIV-infected persons. Studies have also been done in small numbers of HIVuninfected, healthy adults (see Table 10)."}, {"Final_set": {"Context": "The time from initiation of daily oral doses of TDF/FTC to maximal protection against HIV infection is unknown. There is no scientific consensus on the protective intracellular concentrations for either drug or their contribution in specific body tissues. Studies suggest that maximum intracellular concentrations of tenofovir diphosphate (TFV-DP) are reached in blood after approximately 20 days, in rectal tissue at around 7 days, and in cervicovaginal tissues at about 20 days. There is currently no available data on drug concentrations in penile tissues.", "Question": "A 25-year-old sexually active male begins a preventive regimen with daily oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) to reduce his risk of acquiring HIV. After 10 days of adherence to the regimen, he inquires about the timeframe needed to achieve maximal protection. Based on available pharmacokinetic studies, what is the most accurate information he should be given regarding the time to reach maximum levels of protection in rectal tissues?", "Choices": {"A": "Maximum levels of protection in rectal tissues are typically reached after 3 days of daily dosing.", "B": "Maximum levels of protection in rectal tissues are typically reached after 7 days of daily dosing.", "C": "Maximum levels of protection in rectal tissues are typically reached after 14 days of daily dosing.", "D": "Maximum levels of protection in rectal tissues are typically reached after 30 days of daily dosing."}, "Answer": "B: Maximum levels of protection in rectal tissues are typically reached after 7 days of daily dosing. The pharmacokinetic data indicate that steady-state levels of tenofovir diphosphate (TFV-DP) in rectal tissue are achieved around 7 days of daily oral administration of TDF/FTC. This means that after this period, the individual's risk of HIV infection in the rectal mucosa would be significantly reduced."}, "context": "# TIME TO ACHIEVING PROTECTION\nThe time from initiation of daily oral doses of TDF/FTC to maximal protection against HIV infection is unknown. There is not scientific consensus on what intracellular concentrations are protective for either drug or the protective contribution of each drug in specific body tissues. It has been shown that the pharmacokinetics of TDF and FTC vary by tissue 80 .\nData from exploratory pharmacokinetic studies conducted with HIV-uninfected men and women does provide preliminary data on the lead-time required to achieve steady state levels of tenofovir diphosphate (TFV-DP, the activated form of the medication) in blood (PBMCs ), rectal, and vaginal tissues 81,82 . These data suggest that maximum intracellular concentrations of TFV-DP are reached in blood after approximately 20 days of daily oral dosing, in rectal tissue at approximately 7 days, and in cervicovaginal tissues at approximately 20 days. No data are yet available about intracellular drug concentrations in penile tissues susceptible to HIV infection to inform considerations of protection for male insertive sex partners."}, {"Final_set": {"Context": "Pre-exposure prophylaxis (PrEP) for HIV is recommended for individuals at high risk of HIV infection. It is essential to conduct regular testing and assessments while on PrEP. Testing frequency includes: at least every 3 months for HIV testing, pregnancy testing for women who may become pregnant, and a prescription for daily TDF/FTC for up to 90 days. Routine monitoring of renal function (especially eCrCl) is required at least every 6 months, and STI testing is also recommended. If renal function shows a steady decline, additional evaluations may be needed. Evaluating the need for continued PrEP should occur at least once a year.", "Question": "A 28-year-old woman visits the clinic for routine follow-up while on pre-exposure prophylaxis (PrEP) for HIV. During this visit, she is due for her regular assessments. Which of the following assessments should she have scheduled at least every 6 months while on PrEP?", "Choices": {"A": "Evaluation of bone mineral density", "B": "Monitoring of estimated creatinine clearance (eCrCl)", "C": "Assessment of peripheral blood eosinophils", "D": "Screening for hepatitis B and C viruses"}, "Answer": "B: Monitoring of estimated creatinine clearance (eCrCl). The correct answer is B. This is because routine monitoring of renal function, particularly eCrCl, is emphasized for patients on PrEP at least every 6 months. Keeping track of eCrCl allows for early detection of potential renal issues. While other assessments may be important, they are not specifically required every 6 months in the context of PrEP monitoring."}, "context": "\uf0a7 At least every 3 months to o Repeat HIV testing and assess for signs or symptoms of acute infection to document that patients are still HIV negative (see Figure) o Repeat pregnancy testing for women who may become pregnant o Provide a prescription or refill authorization of daily TDF/FTC for no more than 90 days (until the next HIV test) o Assess side effects, adherence, and HIV acquisition risk behaviors o Provide support for medication adherence and risk-reduction behaviors o Respond to new questions and provide any new information about PrEP use \uf0a7 At least every 6 months to o Monitor eCrCl  If other threats to renal safety are present (e.g., hypertension, diabetes), renal function may require more frequent monitoring or may need to include additional tests (e.g., urinalysis for proteinuria)  A rise in serum creatinine is not a reason to withhold treatment if eCrCl remains \u226560 ml/min.  If eCrCl is declining steadily (but still \u226560 ml/min), consultation with a nephrologist or other evaluation of possible threats to renal health may be indicated. o Conduct STI testing recommended for sexually active adolescents and adults (i.e., syphilis, gonorrhea, chlamydia) 83 \uf0a7 At least every 12 months to o Evaluate the need to continue PrEP as a component of HIV prevention OPTIONAL ASSESSMENTS"}, {"Final_set": {"Context": "Therapeutic drug monitoring (TDM) is not routinely utilized in the prevention of HIV infection through pre-exposure prophylaxis (PrEP) due to several challenges. Among these challenges are the absence of established blood concentration thresholds that correlate with efficacy for Tenofovir Disoproxil Fumarate (TDF) or Emtricitabine (FTC) in preventing HIV acquisition in adults and the limited availability of laboratories that adhere to strict quality standards for measuring antiretroviral drug levels. While TDM may be utilized periodically to evaluate adherence to PrEP, it is important to note that plasma or serum drug concentrations indicate only recent dosing and do not definitively reflect consistent long-term adherence. Should drug levels be undetectable or very low, it would warrant interventions to support medication adherence among patients.", "Question": "A physician is considering the use of therapeutic drug monitoring (TDM) for a patient on pre-exposure prophylaxis (PrEP) for HIV. What is the main limitation of TDM in this context?", "Choices": {"A": "TDM provides information on long-term drug adherence rather than recent dosing.", "B": "TDM cannot detect the presence of the drug in the body at all.", "C": "TDM only captures recent doses and cannot accurately reflect long-term adherence.", "D": "TDM is required for all patients on PrEP to ensure effective protection against HIV."}, "Answer": "C: TDM only captures recent doses and cannot accurately reflect long-term adherence. This is the correct answer because while TDM can provide insight into a patient's recent medication ingestion, it does not reliably indicate whether a patient has been consistently adhering to their regimen over an extended period. The limitation of TDM in this scenario is crucial, as it underscores the need for additional support and counseling to promote medication adherence when low drug levels are detected."}, "context": "# THERAPEUTIC DRUG MONI TORING\nSimilar to the limited use of therapeutic drug monitoring (TDM) in the treatment of HIV infection 66 , several factors mitigate against the routine use of TDM during PrEP. These factors include (1) a lack of established concentrations in blood associated with robust efficacy of TDF or FTC for the prevention of HIV acquisition in adults after exposure during penile-rectal or penile-vaginal intercourse 87 and (2) the limited but growing availability of clinical laboratories that perform quantitation of antiretroviral medicine concentrations under rigorous quality assurance and quality control standards.\nHowever, some clinicians may want to use TDM periodically to assess adherence to PrEP medication. If so, a key limitation should be recognized. The levels of medication in serum or plasma reflect only very recent doses, so they are not valid estimates of consistent adherence 88 . However, if medication is not detected or is detected at a very low level, support to reinforce medication adherence would be indicated."}, {"Final_set": {"Context": "Patients may discontinue PrEP medication for several reasons, including personal choice, changed life situations resulting in lowered risk of HIV acquisition, intolerable toxicities, chronic nonadherence to the prescribed dosing regimen despite efforts to improve daily pill-taking, or acquisition of HIV infection. Upon discontinuation for any reason, the following should be documented in the health record: HIV status at the time of discontinuation, reason for PrEP discontinuation, recent medication adherence, and reported sexual risk behavior. For persons with incident HIV infection, specific protocols should be followed. Any person wishing to resume PrEP medications should undergo all the same pre-prescription evaluations as a new candidate for PrEP, alongside a discussion regarding the change in circumstances that reflects the need for resuming the medication.", "Question": "A 30-year-old man who is HIV-negative has been taking pre-exposure prophylaxis (PrEP) for the past year. He expresses a desire to discontinue the medication due to a recent drop in his sexual activity and related concerns about side effects. Which of the following actions should be taken upon his discontinuation of PrEP?", "Choices": {"A": "He should return to the clinic for follow-up only if he develops any symptoms.", "B": "Document his HIV status, reason for discontinuation, and discuss any recent high-risk behaviors he may engage in.", "C": "Immediately start an alternative preventive medication against sexually transmitted infections.", "D": "Recommend he takes the last dose of PrEP only if he believes he will engage in high-risk behavior in the future."}, "Answer": "B: Document his HIV status, reason for discontinuation, and discuss any recent high-risk behaviors he may engage in. The correct answer is B. It is crucial to document the patient's HIV status and understand the reason for discontinuing PrEP to ensure his ongoing safety and assess any potential risk for HIV acquisition. Discussing recent sexual behavior helps in evaluating any risks that may have prompted the decision to stop PrEP and ensures proper management going forward."}, "context": "# Discontinuing PrEP\nPatients may discontinue PrEP medication for several reasons, including personal choice, changed life situations resulting in lowered risk of HIV acquisition, intolerable toxicities, chronic nonadherence to the prescribed dosing regimen despite efforts to improve daily pill-taking, or acquisition of HIV infection.\nUpon discontinuation for any reason, the following should be documented in the health record: \uf0a7 HIV status at the time of discontinuation \uf0a7 Reason for PrEP discontinuation \uf0a7 Recent medication adherence and reported sexual risk behavior For persons with incident HIV infection, see Persons with Documented HIV Infection.\nFor persons with active hepatitis B infection, see Special Clinical Considerations.\nAny person who wishes to resume taking PrEP medications after having stopped should undergo all the same pre-prescription evaluation as a person being newly prescribed PrEP. In addition, a frank discussion should clarify the changed circumstances since discontinuing medication that indicate the need to resume medication, and the commitment to, take it,\n\n# Special Clinical Considerations\nThe patient with certain clinical conditions requires special attention and follow-up by the clinician."}, {"Final_set": {"Context": "In the PrEP trials with heterosexual women, medication was promptly discontinued for those who became pregnant, so the safety for exposed fetuses could not be adequately assessed. A single small study of periconception use of TDF in 46 uninfected women in HIV-discordant couples found no ill effects on the pregnancy and no HIV infections. Additionally, because TDF and FTC are widely used for the treatment of HIV infection and continued during pregnancies that occur, the data on pregnancy outcomes in the Antiretroviral Pregnancy Registry provide no evidence of adverse effects among fetuses exposed to these medications. Providers should educate HIV-discordant couples who wish to become pregnant about the potential risks and benefits of all available alternatives for safer conception and if indicated make referrals for assisted reproduction therapies. Whether or not PrEP is elected, the HIV-infected partner should be prescribed effective antiretroviral therapy before conception attempts to reduce the risk of transmission-related viral load in semen.", "Question": "A couple where one partner is HIV-positive is planning for pregnancy. What is the most important recommendation for the HIV-positive partner prior to conception attempts to minimize the risk of HIV transmission to the uninfected partner?", "Choices": {"A": "Discontinue all medication prior to conception attempts.", "B": "Use barrier protection during intercourse.", "C": "Initiate effective antiretroviral therapy to achieve viral suppression.", "D": "Rely solely on natural conception methods."}, "Answer": "C: Initiate effective antiretroviral therapy to achieve viral suppression. The best answer is C. Achieving viral suppression through effective antiretroviral therapy significantly reduces the viral load in the semen, thereby minimizing the risk of transmission to the uninfected partner during conception attempts. It is crucial for the health of both partners and the future child."}, "context": "In the PrEP trials with heterosexual women, medication was promptly discontinued for those who became pregnant, so the safety for exposed fetuses could not be adequately assessed. A single small study of periconception use of TDF in 46 uninfected women in HIV-discordant couples found no ill effects on the pregnancy and no HIV infections. 92 Additionally, because TDF and FTC are widely used for the treatment of HIV infection and continued during pregnancies that occur, 76,77,93 The data on pregnancy outcomes in the Antiretroviral Pregnancy Registry provide no evidence of adverse effects among fetuses exposed to these medications 94 .\nProviders should educate HIV-discordant couples who wish to become pregnant about the potential risks and benefits of all available alternatives for safer conception 95 and if indicated make referrals for assisted reproduction therapies. Whether or not PrEP is elected, the HIVinfected partner should be prescribed effective antiretroviral therapy before conception attempts 96 : if the infected partner is male, to reduce the risk of transmission-related viral load in semen; and in both sexes, for the benefit of their own health 53 .\nIn addition, health care providers are strongly encouraged to prospectively and anonymously submit information about any pregnancies in which PrEP is used to the Antiretroviral Pregnancy Registry at /."}, {"Final_set": {"Context": "Patients with chronic active hepatitis B virus infection require careful management, especially when considering pre-exposure prophylaxis (PrEP) for HIV. Tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) are effective in suppressing both HIV and HBV. While TDF is FDA-approved for preventing significant liver damage in HBV patients, screening individuals for hepatitis B surface antigen (HBsAg) is crucial before starting PrEP. If a patient tests positive for HBsAg, they should be evaluated by a specialist in HBV management, and monitoring for HBV replication levels is essential every 6-12 months during PrEP. Adherence to TDF/FTC dosing is vital to reduce the risk of HBV reactivation and potential hepatic injury.", "Question": "A 28-year-old man presents for pre-exposure prophylaxis (PrEP) against HIV. He is at high risk for HIV acquisition and has a known history of hepatitis B infection. He is currently asymptomatic but is concerned about the implications of starting PrEP with TDF/FTC. Which of the following is the most important step before initiating PrEP in this patient?", "Choices": {"A": "Starting TDF/FTC immediately since he is asymptomatic", "B": "Conducting a liver biopsy to assess for liver damage", "C": "Testing for hepatitis B surface antigen (HBsAg)", "D": "Advising the patient to increase his dietary intake of liver-friendly foods"}, "Answer": "C: Testing for hepatitis B surface antigen (HBsAg). The best answer is C. Identifying the presence of HBsAg is crucial before starting PrEP because if the patient has chronic active HBV infection, he may require different management to avoid the risk of HBV reactivation or hepatic injury. This screening step ensures that any active infection is appropriately addressed and that the patient receives optimal care tailored to his condition."}, "context": "# PATIENTS WITH CHRONIC ACTIVE HEPATITIS B VIRUS INFECTION\nTDF and FTC are each active against both HIV infection and HBV infection and thus may prevent the development of significant liver disease by suppressing the replication of HBV. Only TDF, however, is currently FDA-approved for this use. Therefore, in persons with substantial risk of both HIV acquisition and active HBV infection, daily doses of TDF/FTC may be especially indicated.\nAll persons screened for PrEP who test positive for hepatitis B surface antigen (HBsAg) should be evaluated by a clinician experienced in the treatment of HBV infection. For clinicians without this experience, co-management with an infectious disease or a hepatic disease specialist should be considered. Patients should be tested for HBV DNA by the use of a quantitative assay to determine the level of HBV replication 99 before PrEP is prescribed and every 6-12 months while taking PrEP.\nTDF presents a very high barrier to the development of HBV resistance. However, it is important to reinforce the need for consistent adherence to the daily doses of TDF/FTC to prevent reactivation of HBV infection with the attendant risk of hepatic injury, and to minimize the possible risk of developing TDF-resistant HBV infection 100 ."}, {"Final_set": {"Context": "Patients with chronic renal failure must be carefully managed regarding their use of medications, including PrEP (pre-exposure prophylaxis). The preferred regimen for PrEP, TDF/FTC (Tenofovir Disoproxil Fumarate/Emtricitabine), has not been evaluated for safety in patients with chronic renal failure. As renal function declines, particularly with an estimated creatinine clearance (eCrCl) of less than 60 ml/min, the risks associated with TDF/FTC may outweigh the potential benefits. This specialized population requires alternative strategies for HIV prevention, and other options must be considered to ensure the patient's safety and effective care.", "Question": "A 28-year-old man with a longstanding history of chronic renal failure presents to a clinic seeking advice on HIV prevention strategies. He has an estimated creatinine clearance of 55 ml/min. Which of the following statements is true regarding the use of PrEP in this patient?", "Choices": {"A": "TDF/FTC is safe and effective for HIV prevention in patients with chronic renal failure with an eCrCl <60 ml/min.", "B": "TDF/FTC is contraindicated for this patient due to his renal status, but alternative HIV prevention strategies are available.", "C": "The safety of TDF/FTC in patients with chronic renal failure has been proven by extensive clinical trials.", "D": "This patient should be prescribed TDF/FTC while closely monitoring his renal function."}, "Answer": "B: TDF/FTC is contraindicated for this patient due to his renal status, but alternative HIV prevention strategies are available. The best answer is B because TDF/FTC has not been proven safe for individuals with chronic renal failure, particularly those with an eCrCl of less than 60 ml/min. Given the risks associated with its use in this population, healthcare providers should consider other HIV prevention options that are appropriate for patients with compromised renal function, ensuring that care is tailored to the safety and needs of the patient."}, "context": "# PATIENTS WITH CHRONIC RENAL FAILURE\nHIV-uninfected patients with chronic renal failure, as evidenced by an eCrCl of <60 ml/min, should not take PrEP because the safety of TDF/FTC for such persons was not evaluated in the clinical trials. TDF is associated with modestly reduced renal function when used as part of an antiretroviral treatment regimen in persons with HIV infection (which itself can affect renal function). Because other HIV prevention options are available, the only PrEP regimen proven effective to date (TDF/FTC) and approved by FDA for PrEP is not indicated for persons with chronic renal failure. 6 ADOLESCENT MINORS 101 As a part of primary health care, HIV screening should be discussed with all adolescents who are sexually active or have a history of injection drug use. Parental/guardian involvement in an adolescent's health care is often desirable but is sometimes contraindicated for the safety of the adolescent. However, laws and regulations that may be relevant for PrEP-related services (including HIV testing), such as those concerning consent, confidentiality, parental disclosure, and circumstances requiring reporting to local agencies, differ by jurisdiction 5 . Clinicians considering providing PrEP to a person under the age of legal adulthood (a minor) should be aware of local laws, regulations, and policies that may apply 102 ."}, {"Final_set": {"Context": "Individuals who experience potential HIV exposure, such as through unprotected sexual intercourse or needle-sharing, should seek medical attention within 72 hours to assess the need for non-occupational post-exposure prophylaxis (nPEP). If the exposure is isolated and the person is determined not to be HIV positive, nPEP should be prescribed. However, for those who may have repeated exposure or are in high-risk situations, it may be more beneficial to start pre-exposure prophylaxis (PrEP), particularly if the person is negative for HIV. It is essential to note that concurrent use of daily PrEP can provide better protection than relying solely on repeated nPEP regimens following isolated exposures.", "Question": "A 28-year-old man presents to the emergency department within 12 hours of engaging in unprotected sexual intercourse with a partner of unknown HIV status. He is anxious and requests treatment to prevent HIV infection. Which of the following would be the most appropriate initial management for him?", "Choices": {"A": "Initiate a 28-day course of PrEP immediately", "B": "Prescribe nPEP for 28 days and schedule follow-up testing", "C": "Advise regular screening for HIV without any immediate treatment", "D": "Refer the patient for counseling and wait for symptoms to develop"}, "Answer": "B: Prescribe nPEP for 28 days and schedule follow-up testing. The best choice is B because the patient has presented within 72 hours of a potential HIV exposure, making him an appropriate candidate for non-occupational post-exposure prophylaxis (nPEP). This treatment regimen should be started as soon as possible to reduce the risk of HIV infection. Although PrEP is valuable for high-risk individuals, it is not the immediate recommendation for someone seeking protection after an isolated exposure. The nPEP is intended for individuals who have had a recent high-risk exposure, and appropriate follow-up is essential to monitor for any potential HIV infection."}, "context": "# NONOCCUPATIONAL POSTEXPOSURE PROPHYLAXIS\nPersons not receiving PrEP who seek care within 72 hours after an isolated sexual or injectionrelated HIV exposure should be evaluated for the potential need for nPEP 104 . If such exposures are not isolated, and the person is determined not to have HIV infection, clinicians should consider beginning PrEP immediately because PrEP during the first 28 days is consistent with a recommended nPEP regimen 104 . If the exposure is isolated (e.g., sexual assault, infrequent condom failure), nPEP should be prescribed, but continued antiretroviral medication is not indicated after completion of the 28-day PEP course.\nPersons who repeatedly seek nPEP should be evaluated for possible PrEP use after confirming they have not acquired HIV infection 105 . Because HIV infection has been reported in association with exposures soon after an nPEP course 98 , daily PrEP may be more protective than repeated episodes of nPEP."}, {"Final_set": {"Context": "While managing patients at high risk for HIV infection, clinicians often recommend pre-exposure prophylaxis (PrEP) using antiretroviral medications. Adherence to PrEP is crucial for its effectiveness, but it may differ from adherence seen in those already diagnosed with HIV. Key factors influencing adherence to medication include the perceived efficacy, the ease of integrating medication into daily life, awareness of potential side effects, and costs associated with treatment. Personalized education and supportive monitoring during the initiation phase of PrEP can enhance adherence. Additionally, understanding that patients' motivations differ based on their health status and treatment goals is important when assessing adherence to PrEP regimens.", "Question": "A 25-year-old man with multiple new sexual partners is interested in starting pre-exposure prophylaxis (PrEP) to reduce his risk of acquiring HIV. Which of the following strategies would most likely improve his adherence to the PrEP regimen?", "Choices": {"A": "Keeping track of his medication intake on a physical calendar", "B": "Starting the PrEP medication without any preliminary counseling", "C": "Educating him about the side effects without discussing benefits", "D": "Implementing a personalized follow-up schedule with reminders and support"}, "Answer": "D: Implementing a personalized follow-up schedule with reminders and support. The best answer is D. Providing personalized follow-up and support has been shown to enhance adherence significantly. This approach addresses the patient's individual needs and helps integrate medication into their daily routine, which is essential for maintaining long-term adherence to PrEP. In contrast, the other options lack the necessary support and education that promote understanding and engagement with the medication regimen."}, "context": "Although many published articles address antiretroviral medication adherence among persons being treated for HIV infection, these findings may be only partially applicable to PrEP users. HIV treatment regimens include more than 2 drugs (commonly including more than 1 pill per day), resulting in an increased pill burden, and the possibility of side effects and toxicities with 3 or more drugs may occur that would not occur with TDF/FTC alone. The motivations of persons being treated for HIV infection and persons trying to prevent HIV infection may differ. Because PrEP will be used in otherwise healthy adults, studies of the use of medications in asymptomatic adults for the prevention of potential serious future health outcomes may also be informative for enhancing adherence to PrEP medications. The most cost-effective interventions for improving adherence to antihypertensive and lipid-lowering medications were initiated soon after the patients started taking medication and involved personalized, regularly scheduled education and symptom management (patients were aware that adherence was being monitored) 110 . Patients with chronic diseases reported that the most important factors in adherence to medications were incorporating medication into their daily routines, knowing that the medications work, believing that the benefits outweigh the risks, knowing how to manage side effects, and low out-of pocket costs. 111,112 When initiating a PrEP regimen, clinicians must educate"}, {"Final_set": {"Context": "Side effects can lead to non-adherence, so clinicians need a plan for addressing them. Clinicians should inform patients about the most common side effects and should work with patients to develop a specific plan for handling them, including the use of specific over-the-counter medications that can mitigate symptoms. Furthermore, the importance of using condoms during sex, especially for patients who decide to stop taking their medications, should be reinforced.", "Question": "A 35-year-old man with human immunodeficiency virus (HIV) is initiated on antiretroviral therapy. During his follow-up visit, he reports experiencing nausea and fatigue, which he fears might lead him to miss doses of his medication. What is the best approach for the clinician to take in addressing the man\u2019s concerns?", "Choices": {"A": "Advise the patient to stop his medication until symptoms resolve", "B": "Educate the patient about common side effects and develop a management plan", "C": "Recommend that the patient switch to a different class of medication immediately", "D": "Suggest that the patient take his medication on an empty stomach to reduce nausea"}, "Answer": "B: Educate the patient about common side effects and develop a management plan. The best answer is B. This approach not only addresses the patient\u2019s current symptoms but also proactively involves the patient in managing side effects, enhancing adherence to the medication regimen. By educating the patient about common side effects and potential management strategies, the clinician empowers the patient while reinforcing the importance of medication adherence and safer sex practices."}, "context": "Side effects can lead to non-adherence, so clinicians need a plan for addressing them. Clinicians should tell patients about the most common side effects and should work with patients to develop a specific plan for handling them, including the use of specific over-the-counter medications that can mitigate symptoms 113 . The importance of using condoms during sex, especially for patients who decide to stop taking their medications, should be reinforced."}, {"Final_set": {"Context": "Effective medication adherence counseling can significantly improve patient outcomes, particularly in chronic conditions such as HIV prevention. A multidisciplinary healthcare team, including physicians, nurses, case managers, and pharmacists, is essential in providing comprehensive counseling. These professionals can work collaboratively to empower patients, tailor interventions to individual needs, and address behavioral risk factors that contribute to non-adherence. Furthermore, supporting the adoption and maintenance of safer behaviors is fundamental for individuals prescribed pre-exposure prophylaxis (PrEP), who must remain vigilant regarding their risks, especially in light of changing partners or life circumstances.", "Question": "What is the primary benefit of employing a multidisciplinary healthcare team in medication adherence counseling for patients at risk of HIV infection?", "Choices": ["A: It allows for a greater focus on clinical trials and research studies.", "B: It provides a comprehensive approach to addressing behavioral risk factors and tailoring advice to individual patient needs.", "C: It reduces medication costs through bulk purchasing strategies.", "D: It increases the time available for individual counseling sessions with a single provider."], "Answer": "The best answer is B. A multidisciplinary healthcare team provides a comprehensive approach to addressing behavioral risk factors, which is critical for patients at risk of HIV infection. This collaboration allows the team to tailor their advice and interventions based on individual patients' changing needs, promoting better adherence to medication and safer behaviors over time."}, "context": "# Box D: Key Components of Medication Adherence Counseling\nUsing a broad array of a health care professionals (e.g., physicians, nurses, case-managers, physician assistants, clinic-based and community pharmacists) that work together on a health care team to influence and reinforce adherence instructions 114 significantly improves medication adherence and may alleviate the time constraints of individual providers. 115,116 This broad-team approach may also provide a larger number of providers to counsel patients about selfmanagement of behavioral risks.\nFor additional information on adherence counseling, see the Clinical Providers' Supplement, Section 6 at .\n\n# Reducing HIV Risk Behaviors\nThe adoption and the maintenance of safer behaviors (sexual, injection, and other substance abuse) are critical for the lifelong prevention of HIV infection and are important for the clinical management of persons prescribed PrEP.  117 have reduced STI incidence in a general clinic population. However, they take a general approach, so they do not allow tailoring to the sexual risk-reduction needs of individual patients (e.g., as partners change, PrEP is initiated or discontinued)."}, {"Final_set": {"Context": "HIV transmission among injection drug users is a significant public health concern. To mitigate this risk, multiple strategies can be applied concurrently. Access to medication-assisted treatment, such as methadone or buprenorphine, can be beneficial for those willing to participate in drug treatment programs. However, for individuals who are not able or willing to seek treatment, harm reduction strategies such as syringe service programs are critical. These programs provide clean syringes and can lead to a decrease in the sharing of injection equipment, thus lowering the risk of HIV and other blood-borne infections. Additionally, referrals for mental health support or behavioral counseling may further reduce high-risk behaviors associated with injection drug use. Such comprehensive approaches are essential in addressing both active substance use and its associated risks.", "Question": "What harm reduction strategy should be prioritized for injection drug users who are not currently seeking drug treatment or are unable to do so due to barriers like insurance issues?", "Choices": ["A: Providing access to mental health counseling exclusively", "B: Offering access to syringe service programs for clean injection equipment", "C: Encouraging hospitalization for substance use disorder treatment", "D: Recommending abstinence from all forms of drug use immediately"], "Answer": "B: Offering access to syringe service programs for clean injection equipment. The best answer is B because syringe service programs are specifically designed to reduce the transmission of HIV and other blood-borne diseases among people who inject drugs. By providing access to clean syringes, these programs can effectively decrease the risk of sharing injection equipment, which is a major route of HIV transmission. While mental health counseling is important, it does not directly address the immediate risks associated with injection drug use as effectively as providing clean equipment does."}, "context": "Reducing or eliminating injection risk practices can be achieved by providing access to drug treatment and relapse prevention services (e.g., methadone, buprenorphine for opiate users) for persons who are willing to participate 125 . For persons not able (e.g., on a waiting list or lacking insurance) or not motivated to engage in drug treatment, providing access to unused injection equipment through syringe service programs (where available), prescriptions for syringes or purchase from pharmacies without a prescription (where legal) can reduce HIV exposure. In addition, providing or referring for cognitive or behavioral counseling and any indicated mental health or social services may help reduce risky injection practices. See the Substance Abuse Treatment and Mental Health Treatment Locators at /.\nFor additional information on risk reduction interventions, see Clinical Providers' Supplement, Section 7 at ."}, {"Final_set": {"Context": "Decision support systems play a crucial role in healthcare by facilitating safe medication management, especially for preventive measures like pre-exposure prophylaxis (PrEP) for HIV. The integration of electronic and paper-based systems, flow sheets, and checklists enhances the clinicians' capacity to guide patients through the various steps required for PrEP usage. Furthermore, these systems may also include apps and digital platforms to provide patients with resources, such as locating nearby sites for confidential HIV tests and tracking adherence to medications. The alignment with various Department of Health and Human Services (DHHS) guidelines indicates a multidisciplinary approach to sexual health and HIV prevention.", "Question": "A healthcare provider is developing a decision support system to assist patients in safely using pre-exposure prophylaxis (PrEP) for HIV. Which of the following features would be most beneficial in improving patient adherence to PrEP medication?", "Choices": ["A: A checklist for clinicians to review all patients on PrEP quarterly", "B: An electronic monitoring system that alerts both patients and providers about missed doses", "C: A brochure explaining the side effects of PrEP medication", "D: A monthly newsletter discussing the latest HIV research findings"], "Answer": "B: An electronic monitoring system that alerts both patients and providers about missed doses. The best answer is B because electronic monitoring systems can significantly improve adherence rates by providing timely reminders and support for both patients and healthcare providers to address missed doses, thereby reducing the risk of HIV transmission. This proactive approach offers real-time feedback, which is critical in managing long-term therapy."}, "context": "# Decision Support, Training and Technical Assistance\nDecision support systems (electronic and paper), flow sheets, checklists (see Clinical Providers' Supplement, Section 1 for a PrEP provider/patient checklist at ), feedback reminders, and involvement of nurse clinicians and pharmacists will be helpful in managing the many steps indicated for the safe use of PrEP and to increase the likelihood that patients will follow them. Often these systems are locally developed but may become available from various sources including training centers and Web sites funded by government agencies; professional associations, or interested private companies. Examples include downloadable applications (widgets) to support the delivery of nPEP or locate nearby sites for confidential HIV tests (); and confidential commercial services to electronically monitor\n\n# Related DHHS Guidelines\nThis document is consistent with several other guidelines from several DHHS agencies related to sexual health, HIV prevention, and the use of antiretroviral medications. Clinicians should refer to these other documents for detailed guidance in their respective areas of care.\n\n# III. Expert opinion\nThe quality of scientific evidence ratings in Table 2 are based on the GRADE rating system. 28\n\n# Appendices"}]